This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with refractory moderate - to - severe active rheumatoid arthritis.
Aged ≥18 years (inclusive of the boundary value), with no restriction on gender.
Expected survival time of at least 3 months.
Subjects with refractory moderate - to - severe active rheumatoid arthritis who have failed standard treatment or lack effective therapeutic options.
Meet the requirements for liver and kidney function, as well as cardiopulmonary function.
A history of malignant tumors other than relapsed/refractory autoimmune diseases (R/R AID) within 5 years prior to screening.
Subjects with positive results in virus/syphilis tests.
Severe cardiac diseases or unstable systemic diseases.
Active or uncontrollable infections requiring systemic treatment within 7 days before administration; evidence of central nervous system invasion at screening.